Upstream Bio (NASDAQ:UPB) Posts Earnings Results, Misses Estimates By $0.06 EPS

Key Points

• EPS miss: Upstream Bio reported a loss of ($0.79) EPS, missing the consensus of ($0.73) by $0.06, and showed deeply negative profitability metrics (ROE -28.71%, net margin -4,366.77%), though revenue beat at $0.67M versus $0.52M expected.
• Stock reaction and valuation: Shares jumped about 7.9% to $10.22 despite the miss; the company has a market cap of ~$552.3M, a 52-week range of $5.14–$33.68, and 50/200-day SMAs of $16.80/$21.50, reflecting recent weakness.
• Analyst and institutional interest: The consensus rating is a "Moderate Buy" with a $45.25 price target amid mixed analyst views (Mizuho upgraded to strong-buy while Weiss reiterated a sell) and several institutions modestly increasing stakes.

Upstream Bio (NASDAQ:UPB - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.06), FiscalAI reports. Upstream Bio had a negative return on equity of 28.71% and a negative net margin of 4,366.77%.The company had revenue of $0.67 million during the quarter, compared to analysts' expectations of $0.52 million.

Upstream Bio Trading Up 7.9%

Shares of Upstream Bio stock traded up $0.75 during trading on Thursday, hitting $10.22. 52,022 shares of the stock traded hands, compared to its average volume of 1,325,713. The stock's fifty day simple moving average is $16.80 and its 200 day simple moving average is $21.50. The firm has a market cap of $552.34 million, a P/E ratio of -5.38 and a beta of 2.96. Upstream Bio has a 52-week low of $5.14 and a 52-week high of $33.68.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in UPB. BNP Paribas Financial Markets raised its holdings in shares of Upstream Bio by 229.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company's stock valued at $34,000 after purchasing an additional 2,158 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of Upstream Bio by 83.0% during the second quarter. Legal & General Group Plc now owns 3,174 shares of the company's stock valued at $35,000 after purchasing an additional 1,440 shares in the last quarter. Empowered Funds LLC purchased a new position in Upstream Bio during the fourth quarter valued at approximately $45,000. Russell Investments Group Ltd. increased its holdings in Upstream Bio by 1,963.9% during the third quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company's stock valued at $57,000 after buying an additional 2,887 shares during the period. Finally, AQR Capital Management LLC bought a new position in Upstream Bio in the first quarter worth approximately $115,000.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Mizuho upgraded shares of Upstream Bio to a "strong-buy" rating in a research note on Thursday, December 18th. Lifesci Capital assumed coverage on shares of Upstream Bio in a research note on Tuesday, December 2nd. They set an "outperform" rating and a $43.00 price target for the company. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Upstream Bio in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $45.25.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio's approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company's research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.